Succès de la cotation du nouvel ensemble Stallergenes Greer sur Euronext Paris


Paris – 8 September 2015– Euronext, the primary exchange in the Euro zone, today announced the successful listing of Stallergenes Greer (currently called Ares Allergy Holding PLC), the world’s leading allergy immunotherapy specialist. Stallergenes Greer was created by the merger of Stallergenes S.A with Greer Laboratories, Inc.  The new entity is listed on the Euronext Paris regulated market in compartment A.

Ares Allergy is an international pharmaceutical company specialising in the diagnosis and treatment of allergies. It develops and markets allergy immunotherapy products and services to provide lasting treatment for allergy-related respiratory diseases. By combining the assets of two top companies in its main markets, the group is now global leader in the fast-growing allergy immunotherapy sector. Ares Allergy has entities in 29 countries and 1,434 employees. In its new form, the Stallergenes Greer group reported revenue of €312.5 million in 2014, and over 500,000 patients were treated with its products.

Fereydoun Firouz, Chairman and CEO of Ares Allergy said: “By combining the resources of Stallergenes and Greer, Ares Allergy has become the worldwide leader in allergy immunotherapies. Anchored on this strong foundation, we are developing a growth strategy to allow allergy sufferers around the globe to live normal lives. Since Stallergenes has been listed on Euronext since its market debut in 1998, we opted to list Ares Allergy in Paris as well, to maintain continuity for all of our shareholders.”

Marc Lefèvre, Euronext’s head of Listing,added: “We are delighted to welcome the new Ares Allergy international group to our Paris market following its cross-border merger. Euronext is now Europe’s leading market for life science companies, with over 90[1]listed, and Ares Allergy’s decision to list here illustrates just how attractive our markets are for these businesses. Euronext offers a springboard for raising companies’ visibility with major international investors, and Ares Allergy will be able to make full use of the many financing and liquidity tools we offer our issuers.”

[1]Including pharmaceutical companies

Press Release Footer

About Euronext 
Euronext is the leading pan-European market infrastructure, connecting European economies to global capital markets, to accelerate innovation and sustainable growth. It operates regulated exchanges in Belgium, France, Ireland, Italy, the Netherlands, Norway and Portugal. With more than 1,900 listed issuers and around €7.1 trillion in market capitalisation as of end March 2024, it has an unmatched blue-chip franchise and a strong diverse domestic and international client base. Euronext operates regulated and transparent equity and derivatives markets, one of Europe’s leading electronic fixed income trading markets and is the largest centre for debt and funds listings in the world. Its total product offering includes Equities, FX, Exchange Traded Funds, Warrants & Certificates, Bonds, Derivatives, Commodities and Indices. The Group provides a multi-asset clearing house through Euronext Clearing, and custody and settlement services through Euronext Securities central securities depositories in Denmark, Italy, Norway and Portugal. Euronext also leverages its expertise in running markets by providing technology and managed services to third parties. In addition to its main regulated market, it also operates a number of junior markets, simplifying access to listing for SMEs.  
For the latest news, follow us on Twitter ( and LinkedIn (

This press release is for information purposes only and is not a recommendation to engage in investment activities. This press release is provided “as is” without representation or warranty of any kind. While all reasonable care has been taken to ensure the accuracy of the content, Euronext does not guarantee its accuracy or completeness. Euronext will not be held liable for any loss or damages of any nature ensuing from using, trusting or acting on information provided. No information set out or referred to in this publication may be regarded as creating any right or obligation. The creation of rights and obligations in respect of financial products that are traded on the exchanges operated by Euronext’s subsidiaries shall depend solely on the applicable rules of the market operator. All proprietary rights and interest in or connected with this publication shall vest in Euronext.

This press release speaks only as of this date. Euronext refers to Euronext N.V. and its affiliates. Information regarding trademarks and intellectual property rights of Euronext is located at

© 2024, Euronext N.V. - All rights reserved.